The stock has a 36-month beta value of 0.81. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QNCX is 35.00M, and at present, short sellers hold a 1.45% of that float. On June 13, 2025, the average trading volume of QNCX was 294.63K shares.
QNCX) stock’s latest price update
The stock price of Quince Therapeutics Inc (NASDAQ: QNCX) has plunged by -4.00 when compared to previous closing price of 1.25, but the company has seen a 0.84% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-12 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $QNCX #biotech–Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants (“Warrants”).
QNCX’s Market Performance
Quince Therapeutics Inc (QNCX) has experienced a 0.84% rise in stock performance for the past week, with a 26.32% rise in the past month, and a -14.89% drop in the past quarter. The volatility ratio for the week is 3.57%, and the volatility levels for the past 30 days are at 4.45% for QNCX. The simple moving average for the last 20 days is 12.00% for QNCX stock, with a simple moving average of -8.07% for the last 200 days.
Analysts’ Opinion of QNCX
Many brokerage firms have already submitted their reports for QNCX stocks, with Oppenheimer repeating the rating for QNCX by listing it as a “Outperform.” The predicted price for QNCX in the upcoming period, according to Oppenheimer is $10 based on the research report published on March 24, 2025 of the current year 2025.
QNCX Trading at 11.71% from the 50-Day Moving Average
After a stumble in the market that brought QNCX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.02% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNCX starting from Thye Dirk, who purchase 77,000 shares at the price of $0.70 back on Aug 30 ’24. After this action, Thye Dirk now owns 843,941 shares of Quince Therapeutics Inc, valued at $53,900 using the latest closing price.
Thye Dirk, the CEO AND CHIEF MEDICAL OFFICER of Quince Therapeutics Inc, purchase 77,500 shares at $0.69 during a trade that took place back on Aug 29 ’24, which means that Thye Dirk is holding 766,941 shares at $53,475 based on the most recent closing price.
Stock Fundamentals for QNCX
The total capital return value is set at -0.62. Equity return is now at value -130.90, with -45.58 for asset returns.
Based on Quince Therapeutics Inc (QNCX), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -2.12.
Currently, EBITDA for the company is -56.55 million with net debt to EBITDA at -0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.05.
Conclusion
To sum up, Quince Therapeutics Inc (QNCX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
